XML 41 R34.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Segment Reporting [Abstract] |
Schedule of Segment Information | The following tables set forth our segment information for the three and nine months ended September 30, 2024 and 2023, respectively (in thousands):
|  | Three Months Ended September 30, 2024 |
|  | MRD |  |  | Immune Medicine |  |  | Unallocated Corporate |  |  | Total |
Revenue |  | $ | 37,470 |  |  | $ | 8,965 |  |  | $ | — |  |  | $ | 46,435 |
Operating expenses |  |  | 52,538 |  |  |  | 20,689 |  |  |  | 5,840 |  |  |  | 79,067 |
Adjusted EBITDA(1) |  |  | (6,120 | ) |  |  | (5,212 | ) |  |  | (2,968 | ) |  |  | (14,300 | )
Reconciliation of Net Loss to Adjusted EBITDA: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (15,068 | ) |  | $ | (11,724 | ) |  | $ | (5,305 | ) |  | $ | (32,097 | )
Net loss attributable to noncontrolling interest |  |  | — |  |  |  | — |  |  |  | 26 |  |  |  | 26 |
Net loss attributable to Adaptive Biotechnologies Corporation |  |  | (15,068 | ) |  |  | (11,724 | ) |  |  | (5,279 | ) |  |  | (32,071 | )
Interest and other income, net |  |  | — |  |  |  | — |  |  |  | (3,474 | ) |  |  | (3,474 | )
Interest expense(2) |  |  | — |  |  |  | — |  |  |  | 2,939 |  |  |  | 2,939 |
Depreciation and amortization expense |  |  | 2,428 |  |  |  | 1,728 |  |  |  | 435 |  |  |  | 4,591 |
Restructuring expense(3) |  |  | 167 |  |  |  | 26 |  |  |  | — |  |  |  | 193 |
Share-based compensation expense(4) |  |  | 6,353 |  |  |  | 4,758 |  |  |  | 2,411 |  |  |  | 13,522 |
Adjusted EBITDA(1) |  | $ | (6,120 | ) |  | $ | (5,212 | ) |  | $ | (2,968 | ) |  | $ | (14,300 | )
|  | Three Months Ended September 30, 2023 |
|  | MRD |  |  | Immune Medicine |  |  | Unallocated Corporate |  |  | Total |
Revenue |  | $ | 24,668 |  |  | $ | 13,251 |  |  | $ | — |  |  | $ | 37,919 |
Operating expenses |  |  | 55,977 |  |  |  | 26,400 |  |  |  | 6,498 |  |  |  | 88,875 |
Adjusted EBITDA(1) |  |  | (21,616 | ) |  |  | (4,986 | ) |  |  | (3,229 | ) |  |  | (29,831 | )
Reconciliation of Net Loss to Adjusted EBITDA: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (31,309 | ) |  | $ | (13,148 | ) |  | $ | (5,869 | ) |  | $ | (50,326 | )
Net loss attributable to noncontrolling interest |  |  | — |  |  |  | — |  |  |  | 26 |  |  |  | 26 |
Net loss attributable to Adaptive Biotechnologies Corporation |  |  | (31,309 | ) |  |  | (13,148 | ) |  |  | (5,843 | ) |  |  | (50,300 | )
Interest and other income, net |  |  | — |  |  |  | — |  |  |  | (4,282 | ) |  |  | (4,282 | )
Interest expense(2) |  |  | — |  |  |  | — |  |  |  | 3,652 |  |  |  | 3,652 |
Depreciation and amortization expense |  |  | 2,489 |  |  |  | 2,546 |  |  |  | 728 |  |  |  | 5,763 |
Share-based compensation expense(4) |  |  | 7,204 |  |  |  | 5,616 |  |  |  | 2,516 |  |  |  | 15,336 |
Adjusted EBITDA(1) |  | $ | (21,616 | ) |  | $ | (4,986 | ) |  | $ | (3,229 | ) |  | $ | (29,831 | )
|  | Nine Months Ended September 30, 2024 |
|  | MRD |  |  | Immune Medicine |  |  | Unallocated Corporate |  |  | Total |
Revenue |  | $ | 105,380 |  |  | $ | 26,118 |  |  | $ | — |  |  | $ | 131,498 |
Operating expenses |  |  | 170,785 |  |  |  | 70,663 |  |  |  | 18,762 |  |  |  | 260,210 |
Adjusted EBITDA(1) |  |  | (34,668 | ) |  |  | (19,172 | ) |  |  | (10,086 | ) |  |  | (63,926 | )
Reconciliation of Net Loss to Adjusted EBITDA: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (65,405 | ) |  | $ | (44,545 | ) |  | $ | (15,928 | ) |  | $ | (125,878 | )
Net loss attributable to noncontrolling interest |  |  | — |  |  |  | — |  |  |  | 78 |  |  |  | 78 |
Net loss attributable to Adaptive Biotechnologies Corporation |  |  | (65,405 | ) |  |  | (44,545 | ) |  |  | (15,850 | ) |  |  | (125,800 | )
Interest and other income, net |  |  | — |  |  |  | — |  |  |  | (11,462 | ) |  |  | (11,462 | )
Interest expense(2) |  |  | — |  |  |  | — |  |  |  | 8,628 |  |  |  | 8,628 |
Depreciation and amortization expense |  |  | 7,733 |  |  |  | 5,777 |  |  |  | 1,298 |  |  |  | 14,808 |
Impairment of long-lived assets(3) |  |  | 2,819 |  |  |  | 4,386 |  |  |  | — |  |  |  | 7,205 |
Restructuring expense(3) |  |  | 1,195 |  |  |  | 722 |  |  |  | — |  |  |  | 1,917 |
Share-based compensation expense(4) |  |  | 18,990 |  |  |  | 14,488 |  |  |  | 7,300 |  |  |  | 40,778 |
Adjusted EBITDA(1) |  | $ | (34,668 | ) |  | $ | (19,172 | ) |  | $ | (10,086 | ) |  | $ | (63,926 | )
|  | Nine Months Ended September 30, 2023 |
|  | MRD |  |  | Immune Medicine |  |  | Unallocated Corporate |  |  | Total |
Revenue |  | $ | 71,977 |  |  | $ | 52,515 |  |  | $ | — |  |  | $ | 124,492 |
Operating expenses |  |  | 170,946 |  |  |  | 88,753 |  |  |  | 20,760 |  |  |  | 280,459 |
Adjusted EBITDA(1) |  |  | (71,081 | ) |  |  | (11,149 | ) |  |  | (9,518 | ) |  |  | (91,748 | )
Reconciliation of Net Loss to Adjusted EBITDA: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (98,969 | ) |  | $ | (36,236 | ) |  | $ | (20,632 | ) |  | $ | (155,837 | )
Net loss attributable to noncontrolling interest |  |  | — |  |  |  | — |  |  |  | 28 |  |  |  | 28 |
Net loss attributable to Adaptive Biotechnologies Corporation |  |  | (98,969 | ) |  |  | (36,236 | ) |  |  | (20,604 | ) |  |  | (155,809 | )
Interest and other income, net |  |  | — |  |  |  | — |  |  |  | (10,918 | ) |  |  | (10,918 | )
Interest expense(2) |  |  | — |  |  |  | — |  |  |  | 10,788 |  |  |  | 10,788 |
Depreciation and amortization expense |  |  | 6,812 |  |  |  | 7,907 |  |  |  | 2,120 |  |  |  | 16,839 |
Share-based compensation expense(4) |  |  | 21,076 |  |  |  | 17,180 |  |  |  | 9,096 |  |  |  | 47,352 |
Adjusted EBITDA(1) |  | $ | (71,081 | ) |  | $ | (11,149 | ) |  | $ | (9,518 | ) |  | $ | (91,748 | )
(1) Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management. (2) Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement. (3) Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expenses. (4) Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration